Syncom Formulations (India) Ltd Quarterly Results
Q3 FY25-26 Results Summary
Revenue
The revenue stands at ₹115.14 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 5.41 per cent from ₹121.72 crore. This corresponds to a year-on-year *(YoY) decline of 9.72 per cent.
Operating Profit
Operating Profit stands at ₹21.21 crore, reflecting a quarter-on-quarter *(QoQ) increase of 15.27 per cent from ₹18.40 crore. This corresponds to a year-on-year *(YoY) growth of 43.99 per cent.
PBDT
PBDT stands at ₹26.45 crore, reflecting a quarter-on-quarter *(QoQ) increase of 13.08 per cent from ₹23.39 crore. This corresponds to a year-on-year *(YoY) growth of 42.43 per cent.
Profit Before Tax
Profit Before Tax stands at ₹25.09 crore, reflecting a quarter-on-quarter *(QoQ) increase of 13.84 per cent from ₹22.04 crore. This corresponds to a year-on-year *(YoY) growth of 45.37 per cent.
Net Profit
Net Profit stands at ₹18.91 crore, reflecting a quarter-on-quarter *(QoQ) increase of 13.92 per cent from ₹16.60 crore. This represents a 45.46 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Market News
Syncom Formulations (India) Ltd Earnings
- YOY
- QOQ
Syncom Formulations (India) Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Syncom Formulations (India) Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Syncom Formulations (India) Ltd Financial Reports
Syncom Formulations (India) Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Syncom Formul. | 4.38% | 2.03% | 36.41% | 11.60% | -16.07% | -16.37% |
| NGL Fine Chem | 1.88% | 0.10% | 9.89% | 27.51% | 57.08% | 107.85% |
| Jagsonpal Pharma | 2.26% | 1.98% | 10.63% | 26.56% | -8.42% | -10.27% |
| Shukra Pharma. | -4.60% | -1.64% | 2.57% | -27.02% | -27.10% | 84.91% |
| Venus Remedies | -0.86% | -10.53% | 13.92% | 19.86% | 115.41% | 202.27% |
| Lincoln Pharma. | 3.39% | 2.38% | 10.57% | 40.05% | 17.59% | 7.02% |
| Ind-Swift Labs. | -1.38% | -4.92% | 2.85% | 26.01% | 31.60% | 77.62% |
Company Info
Company Information
Chairman & Exec. Director : Kedarmal Bankda
ED / MD / Promoter : Vijay Bankda
Independent Non Exe. Director : Ruchi Jindal
Independent Non Exe. Director : Ritesh Kumar Lunkad
Independent Non Exe. Director : Ankit Jain
Chairman / Executive Director / WTD : ANKIT KEDARMAL BANKDA
Company Sec. & Compli. Officer : Vaishali Agrawal